Share on StockTwits

Stock analysts at Robert W. Baird hoisted their price objective on shares of PAREXEL International (NASDAQ:PRXL) from $64.00 to $66.00 in a report issued on Thursday. The firm currently has an “outperform” rating on the stock. Robert W. Baird’s price objective indicates a potential upside of 21.48% from the stock’s previous close.

Several other analysts have also recently commented on the stock. Analysts at Jefferies Group raised their price target on shares of PAREXEL International from $58.00 to $59.00 in a research note on Thursday. Separately, analysts at KeyCorp initiated coverage on shares of PAREXEL International in a research note on Wednesday, July 2nd. They set a “hold” rating on the stock. Finally, analysts at Wells Fargo & Co. upgraded shares of PAREXEL International to a “priority list” rating in a research note on Thursday, June 26th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $56.02.

PAREXEL International (NASDAQ:PRXL) traded up 0.26% on Thursday, hitting $54.47. 204,482 shares of the company’s stock traded hands. PAREXEL International has a one year low of $37.53 and a one year high of $57.25. The stock has a 50-day moving average of $53.88 and a 200-day moving average of $51.6. The company has a market cap of $3.098 billion and a price-to-earnings ratio of 26.32.

PAREXEL International (NASDAQ:PRXL) last released its earnings data on Wednesday, August 6th. The company reported $0.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.03. The company had revenue of $510.60 million for the quarter, compared to the consensus estimate of $508.99 million. During the same quarter in the previous year, the company posted $0.50 earnings per share. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. Analysts expect that PAREXEL International will post $2.67 EPS for the current fiscal year.

PAREXEL International Corporation (NASDAQ:PRXL) is a biopharmaceutical services company, providing a range of expertise in clinical research, medical communications, consulting, and advanced technology products and services to the worldwide pharmaceutical, biotechnology, and medical device industries.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.